Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high‐risk, nonmuscle–invasive bladder cancer treated with tislelizumab plus nanoparticle albumin‐bound paclitaxel
Cancer · 2026
DOI: 10.1002/cncr.70498 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer, 2026. Verfasst von Shiwang Huang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, Magnetic Resonance Imaging, Antibodies, Monoclonal, Humanized, Albumin-Bound Paclitaxel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Key R&D Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Patients with very high‐risk (VHR), nonmuscle–invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy face limited treatment options. Immune checkpoint inhibitor–based regimens have demonstrated promise but lack reliable biomarkers to guide patient selection. The objective of this study was to identify magnetic resonance imaging–derived radiomic phenotypes predictive of treatment response to immune checkpoint inhibitor–based therapy.
Methods
The authors retrospectively analyzed two prospective cohorts of patients with extensive VHR NMIBC: a single‐center derivation cohort from the TRUCE‐02 trial ( n = 59) and a multicenter validation cohort from the TRUCE‐22 trial ( n = 37). All patients received tislelizumab and nanoparticle albumin‐bound paclitaxel every 3 weeks. Complete response (CR) was assessed at 3 months. Radiomic features were extracted from baseline, T2‐weighted images, and a hybrid framework integrating supervised feature selection with unsupervised clustering was used to identify imaging phenotypes. Associations with CR, progression‐free and overall survival, and immune‐related transcriptional signatures were evaluated.
Results
Three radiomic clusters were identified: immune‐excluded (cluster 0), immune‐intermediate (cluster 1), and immune‐inflamed (cluster 2). In the derivation cohort, cluster 2 had a significantly higher CR rate (82.8%) than cluster 0 (21.4%; p = .001), a pattern that was validated in TRUCE‐22 (83.3% vs. 22.2%; p = .008). The cluster‐only model achieved the highest predictive performance for CR in both the derivation (area under the receiver operating characteristic curve, 0.77) and validation (area under the receiver operating characteristic curve, 0.78) cohorts. Cluster 2 had better progression‐free and overall survival. Transcriptomic and immunofluorescence analyses revealed functional immune suppression in cluster 0, including reduced CD8‐positive, phosphorylated STAT1–positive T cells.
Conclusions
In patients with very high‐risk NMIBC, magnetic resonance imaging–derived radiomic phenotypes can be used to stratify responses to immunochemotherapy and capture functional immune states. Noninvasive radiomic profiling may guide precision treatment selection in patients who are unfit for radical cystectomy, and prospective validation is warranted before clinical adoption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
- Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
- Department of Medical Imaging Technology, Tianjin Medical University, Tianjin, China.
- Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin, China.
- Department of Pathology, The Second Hospital of Tianjin Medical University, Tianjin, China.
- Department of Health Statistics, School of Public Health, Tianjin Medical University, Tianjin, China.
ORCID-Profile: Hailong Hu
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Key R&D Program of China
- National Natural Science Foundation of China
- Project of Science and Technology Plan of Tianjin City
- Ascent Plan of Tianjin Medical University Disciplines-Integrated Chinese and Western Medicine
- Scientific Research Project of Tianjin Municipal Health Commission
- Tianjin Institute of Urology Talent Funding Program
- Clinical Medicine Research Project of the Second Hospital of Tianjin Medical University
Zitieren
APA
Huang, S., Jia, K., Liang, S., Ma, B., Chen, H., Zhang, Z., Kang, N., Wu, Z., Lin, Y., Li, P., Xue, Z., Chen, H., Zhao, Y., Guo, J., Li, C., Chai, W., Cui, J., Xu, G., Qie, Y., …, & Hu, H. (2026). Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high‐risk, nonmuscle–invasive bladder cancer treated with tislelizumab plus nanoparticle albumin‐bound paclitaxel. Cancer. https://doi.org/10.1002/cncr.70498
Vancouver
Huang S, Jia K, Liang S, Ma B, Chen H, Zhang Z, et al. Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high‐risk, nonmuscle–invasive bladder cancer treated with tislelizumab plus nanoparticle albumin‐bound paclitaxel. Cancer. 2026. doi:10.1002/cncr.70498
BibTeX
@article{Huang2026,
author = {Huang, Shiwang and Jia, Kaipeng and Liang, Shan and Ma, Boyue and Chen, Huitong and Zhang, Zhe and Kang, Ning and Wu, Zhouliang and Lin, Yuda and Li, Peng and Xue, Zihan and Chen, Houyuan and Zhao, Yang and Guo, Jianing and Li, Changping and Chai, Wang and Cui, Jingmin and Xu, Guoping and Qie, Yunkai and Shen, Chong and Hu, Hailong},
title = {Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high‐risk, nonmuscle–invasive bladder cancer treated with tislelizumab plus nanoparticle albumin‐bound paclitaxel},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70498}
}
EUVIMED